Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Novartis (NVS - Snapshot Report) presented encouraging new data on its ophthalmology drug Lucentis at the European Society of Retina Specialists (EURETINA) in Germany.

Lucentis is approved for wet age-related macular degeneration (AMD) in over 100 countries. It is also approved for the treatment of visual impairment due to diabetic macular edema (DME) and macular edema secondary to branch- and central-retinal vein occlusion (BRVO and CRVO), and choroidal neovascularization secondary to pathologic myopia (myopic CNV).

The data observed in the phase III study, RADIANCE, showed that Lucentis was superior to current standard of care and improved mean visual acuity by around 14 letters at one year with a median of two injections.

Additionally, the data from various trials indicate that early treatment initiation with Lucentis will result in better vision gains in DME patients.

We note that Novartis has a collaboration agreement with Roche’s (RHHBY - Analyst Report) Genentech for Lucentis.

While Roche holds the commercial rights of Lucentis in the U.S., Novartis holds the rights to develop and market Lucentis outside the U.S.

We remind investors that Novartis also pays royalties to Roche on net Lucentis sales outside the U.S.

Lucentis, one of the key drivers of revenue growth for Novartis in 2012, generated sales of $1.2 billion in 1H13, up 1% year over year.

In Jul 2013, Lucentis was approved to treat patients with visual impairment due to CNV, secondary to myopic CNV in Europe as well.

Label expansion for the additional indication will further boost sales of the drug, which bodes well for both Novartis and Roche.

Novartis currently carries a Zacks Rank #3 (Hold). Right now, Bayer (BAYRY - Analyst Report) and Novo Nordisk (NVO - Analyst Report) look attractive with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GENERAL FINA GFN 8.20 +5.67%
QIHOO 360 TE QIHU 91.57 +4.38%
VIPSHOP HOLD VIPS 140.01 +3.49%
INVESTMENT T ITG 19.16 +3.34%
VERTEX ENERG VTNR 7.38 +3.07%